To overcome the action of TGF cytokine’s immunosuppressive actions of the TME, the use of mesothelin-targeted chimeric antigen receptor T cell therapy together with an oncolytic adenovirus (rAd.sT) expressing sTGFβRIIFc (soluble transforming growth factor beta receptor II-Fc fusion protein) demonstrated enhanced anti-tumor responses against breast cancer tumor cells (24). This evidence concerns the gene TGFBR2 and neoplasm.